medigraphic.com
ISSN 0035-0052 (Impreso)

2010, Número 5

<< Anterior Siguiente >>

Rev Mex Pediatr 2010; 77 (5)


Sangre reconstituida, no fresca, en la exanguinotransfusión de un neonato con enfermedad hemolítica por Rh

Caballero-Noguéz B, Rodríguez-Bucheli JE, Trejo MJL, López CR

Idioma: Español
Referencias bibliográficas: 30
Paginas: 209-214
Archivo PDF: 141.48 Kb.


RESUMEN

La exanguinotransfusión es un procedimiento con alta morbilidad y mortalidad, que se hace en neonatos con enfermedad hemolítica por Rh, para reducir las complicaciones, sobre todo de tipo metabólico. Se recomienda hacerla con sangre fresca total reconstituida, de preferencia con menos de 72 h de extracción. Se informa el caso de un recién nacido con 40.1 semanas de gestación con enfermedad hemolítica por Rh, por lo que fue manejado con exanguinotransfusión utilizando sangre total reconstituida de 13 días.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Perlman M, Fainmesser P, Sohmer H, Tamari H, Wax Y, Pevsmer B. Aauditory nerve-brainstem evoked responses in hyperbilirubinemic neonates. Pediatrics 1983; 72: 658-64.

  2. Vohr BR, Lester B, Rapisardi G, O’Dea C, Brown L, Peucker M, Cashore W, Oh W. Aabnormal brain-stem function (brain-stem auditory evoked response) correlates with acoustic cry features in term infants with hyperbilirubinemia. J Pediatr 1989; 115: 303-8.

  3. Tan KL, Skurr BAa, Yip YY. Phototherapy and the brain-stem auditory evoked response in neonatal hyperbilirubinemia. J Pediatr 1992; 120(2 ptl): 306-8.

  4. Gupta AaK, Mann SB. In auditory brainstem response a bilirubin neurotoxicity marker? Am J Otolaryngol 1998; 19: 232-6.

  5. Sabatino G, Verrotti Aa, Ramenghi LAa, Domizio S, Melchionda D, Fulgente T et al. Newborns with hyperbilirubinemia: usefulness of brainstem auditory response evaluation. Neurophysiol Clin 1996; 26: 363-8.

  6. Hansen TW. Kernicterus: an international perspective. Semin Neonatol 2002; 7: 103-9.

  7. Ebbesen F. Recurrence of kernicterus in term and near-term infants in Denmark. Acta Paediatr 2000; 89: 1213-7.

  8. Bertini G, Dani C, Pezzati M, Rubaltelli FF. Prevention of bilirubin encephalopathy. Biol Neonate 2001; 79: 219-23.

  9. Hsia D, Aallen F, Cellis S, Diamond I. Erythroblastosis fetalis. VIII. Studies of serum bilirubin in relation to kernicterus. N Engl J Med 1952; 247: 668-71.

  10. Ip S, Lau J, Chung M, Kulig J, Sege R, Glicken S, O’Brien R. Hyperbilirubinemia and kernicterus: 50 years later. Pediatrics 2004; 114: 263-4.

  11. Ip S, Chung M, Kulig J, O’Brien R, Sege R, Glicken S et al. Am Acad Pediatr. Subcommittee on Hyperbilirubinemia. Aan evidence- based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004; 114: 130-53.

  12. Weisz B, Belson Aa, Milbauer B, Raif S. Complications of exchange transfusion in term and preterm newborns. Harefuah 1996; 130: 170-3.

  13. Rühl H, Bein G, Sachs UJ. Transfusion-associated graft-vs-host disease. Transf Med Rev 2009; 23: 62-71.

  14. AA aaP. Provisional Committee for quality improvement and subcommitteeon hyperbilirubinemia: Practice parameters management of hyperbilirubinemia in the healthy term newborn. Pediatrics 1994; 94: 558-65.

  15. aaP. Subcommittee on Hyperbilirubinemia: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 297-316.

  16. A abu-Ekteish F, Daoud Aa, Rimawi H, Kakish K, Aabu-Heija Aa. Neonatal exchange transfusion: a Jordanian experience. Ann Trop Paediatr 2000; 20: 57-60.

  17. Jackson JC. Aadverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 1997; 99: 5.

  18. Patra K, Storfer-Isser Aa, Siner B, Moore J, Hack M. events associated with neonatal exchange transfusion in the 1990s. J Pediatr 2004; 144: 662-3.

  19. Hovi L, Siimes MAa. Exchange transfusion with fresh heparinized blood is a safe procedure. Experiences from 1,069 newborns. Acta Paediatr Scand 1985; 74: 360-5.

  20. asociación Mexicana de Medicina Transfusional. Guía para el uso clínico de la sangre. México. Secretaría de Salud de México 2007.

  21. Keenan WJ, Novak KK, Sutherland JM, Bryla DAa, Fetterly KL. Morbidity and mortality associated with exchange transfusion. Pediatrics 1985; 75(Suppl): 417-21.

  22. Chima RS, Johnson LH, Bhutani BK. Evaluation of adverse events due to exchange transfusion in term and near-term newborns (abstract). Pediatr Res 2001; 49: 324Aa.

  23. Kappas Drummond GS, Munson DP, Marshall JR. Sn-Mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah’s Witness newborns as an alternative to exchange transfusion. Pediatrics 2001; 108: 1374-7.

  24. Suresh GK, Martin CL, Soli RF. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates. Cochrane Database Syst Rev 2003; 2: CD004207.

  25. Caballero NB, Hernández PS, Rodríguez-Bucheli JE, Quiroz MM, Flores CI. Efecto del clofibrato asociado a fototerapia sobre la concentración de bilirrubina en niños recién nacidos. Rev Mex Pediatr 2001; 68: 176-80.

  26. Zahedpasha Y, Aahmadpour-Kacho M, Hajiahmadi M, Naderi S. Effect of clofibrate in jaundiced full-term infants: Aa randomized clinical trial. Archives of Iranian Medicine 2007; 10: 349-53.

  27. Maisels MJ. Is exchange transfusion for hyperbilirubinemia in danger of becoming extinct? Pediatr Res 1999; 45: 210Aa.

  28. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: a kinder, gentler approach. Pediatrics 1992; 89: 809-18.

  29. Kaplan M, Hammerman C. Aamerican Aacademy of Pediatrics Guidelines for detecting neonatal hyperbilirubinemia and preventing kernicterus. Arch Dis Child Fetal Neonat 2005; 90: 448-9.

  30. Kaplan M, Merlob P, Regev R. Israel guidelines for the management of neonatal hyperbilirubinemia and prevention of kernicterus. J Perinatol 2008; 28: 389-97.




2020     |     www.medigraphic.com